Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 12 of 39, showing 5 Applications out of 195 total, starting on record 56, ending on 60

# Protocol No Study Title Investigator(s) & Site(s)

56.

ECCT/25/03/01   MK-5684_MSD (mCRPC)
     A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)    
Principal Investigator(s)
1. PROF MANSOOR NOORALI SALEH
Site(s) in Kenya
AGA KHAN UNIVERSITY HOSPITAL NAIROBI
 
View

57.

ECCT/20/09/02   BEe-HIVe
     B-ENHANCEMENT OF HBV VACCINATIONIN PERSONS LIVING WITH HIV (BEe-HIVe) EVALUATION OF HEPLISAV-B,A5379   
Principal Investigator(s)
1. JOSPHAT KOSGEI
Site(s) in Kenya
KEMRI/KERICHO CLINIC RESEARCH CENTRE
 
View

58.

ECCT/19/12/02   VPM1002 Phase III PoI
    A multicenter, Phase III double blind, randomized active controlled study to evaluate efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants.     
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI-CRDR Nairobi (Nairobi City county)
2. KEMRI-CRDR Siaya (Siaya county)
 
View

59.

ECCT/15/02/03   IVERMAL study
    Efficacy and safety of high-dose Ivermectin for reducing malaria transmission: A dose finding study   
Principal Investigator(s)
1. Menno Roderick Smit
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) (Kisumu county)
2. Kisumu District Hospital (KDH), (Kisumu county)
3. Siaya District Hospital (Siaya county)
4. Vihiga District Hospital (Vihiga county)
 
View

60.

ECCT/23/04/05   BiMVaC01
    A randomised, controlled clinical trial to assess and compare the immunogenicity, safety and reactogenicity of the bivalent Omicron BA.4/BA.5 adapted, and the original Wuhan-Hu-1-strain, BNT162b2 COVID-19 vaccine formulations in healthy unvaccinated East African adults.   
Principal Investigator(s)
1. NDUNGU FRANCIS
2. Said Jongo
Site(s) in Kenya
KEMRI-CGMRC Kilifi
 
View